BACKGROUND: Histological evidence of pervasive inflammatory infiltrate has been noted in both benign prostatic hyperplasia/hypertrophy (BPH) and prostate cancer (PCa). Cytokines known to attract particular leukocyte subsets are secreted from prostatic stroma consequent to aging and also from malignant prostate epithelium. Therefore, we hypothesized that leukocytes associated with either acute or chronic inflammation attracted to the prostate consequent to aging or tumorigenesis may promote the abnormal cellular proliferation associated with BPH and PCa. METHODS: An in vitro system designed to mimic the human prostatic microenvironment incorporating prostatic stroma (primary and immortalized prostate stromal fibroblasts), epithelium (N15C6, BPH-1, LNCaP, and PC3 cells), and inflammatory infiltrate (HL-60 cells, HH, and Molt-3 T-lymphocytes) was developed. Modified Boyden chamber assays were used to test the ability of prostate stromal and epithelial cells to attract leukocytes and to test the effect of leukocytes on prostate cellular proliferation. Antibody arrays were used to identify leukocyte-secreted cytokines mediating prostate cellular proliferation. RESULTS: Leukocytic cells migrated towards both prostate stromal and epithelial cells. CD4+ T-lymphocytes promoted the proliferation of both transformed and non-transformed prostate epithelial cell lines tested, whereas CD8+ T-lymphocytes as well as dHL-60M macrophagic and dHL-60N neutrophilic cells selectively promoted the proliferation of PCa cells. CONCLUSIONS: The results of these studies show that inflammatory cells can be attracted to the prostate tissue microenvironment and can selectively promote the proliferation of non-transformed or transformed prostate epithelial cells, and are consistent with differential role(s) for inflammatory infiltrate in the etiologies of benign and malignant proliferative disease in the prostate. Prostate 70: 377-389, 2010. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: Histological evidence of pervasive inflammatory infiltrate has been noted in both benign prostatic hyperplasia/hypertrophy (BPH) and prostate cancer (PCa). Cytokines known to attract particular leukocyte subsets are secreted from prostatic stroma consequent to aging and also from malignant prostate epithelium. Therefore, we hypothesized that leukocytes associated with either acute or chronic inflammation attracted to the prostate consequent to aging or tumorigenesis may promote the abnormal cellular proliferation associated with BPH and PCa. METHODS: An in vitro system designed to mimic the human prostatic microenvironment incorporating prostatic stroma (primary and immortalized prostate stromal fibroblasts), epithelium (N15C6, BPH-1, LNCaP, and PC3 cells), and inflammatory infiltrate (HL-60 cells, HH, and Molt-3 T-lymphocytes) was developed. Modified Boyden chamber assays were used to test the ability of prostate stromal and epithelial cells to attract leukocytes and to test the effect of leukocytes on prostate cellular proliferation. Antibody arrays were used to identify leukocyte-secreted cytokines mediating prostate cellular proliferation. RESULTS:Leukocytic cells migrated towards both prostate stromal and epithelial cells. CD4+ T-lymphocytes promoted the proliferation of both transformed and non-transformed prostate epithelial cell lines tested, whereas CD8+ T-lymphocytes as well as dHL-60M macrophagic and dHL-60N neutrophilic cells selectively promoted the proliferation of PCa cells. CONCLUSIONS: The results of these studies show that inflammatory cells can be attracted to the prostate tissue microenvironment and can selectively promote the proliferation of non-transformed or transformed prostate epithelial cells, and are consistent with differential role(s) for inflammatory infiltrate in the etiologies of benign and malignant proliferative disease in the prostate. Prostate 70: 377-389, 2010. (c) 2009 Wiley-Liss, Inc.
Authors: Lesa Begley; David Keeney; Ben Beheshti; Jeremy A Squire; Rajiv Kant; Hassan Chaib; James W MacDonald; Johng Rhim; Jill A Macoska Journal: Genes Chromosomes Cancer Date: 2006-02 Impact factor: 5.006
Authors: Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz Journal: Mol Cell Biol Date: 2006-10-09 Impact factor: 4.272
Authors: Thomas T Murooka; Mark M Wong; Ramtin Rahbar; Beata Majchrzak-Kita; Amanda E I Proudfoot; Eleanor N Fish Journal: J Biol Chem Date: 2006-06-28 Impact factor: 5.157
Authors: William A Boisvert; David M Rose; Kristen A Johnson; Maria E Fuentes; Sergio A Lira; Linda K Curtiss; Robert A Terkeltaub Journal: Am J Pathol Date: 2006-04 Impact factor: 4.307
Authors: Catherine Murphy; Maryalice McGurk; Johanna Pettigrew; Alfredo Santinelli; Roberta Mazzucchelli; Patrick G Johnston; Rodolfo Montironi; David J J Waugh Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Christopher F MacManus; Johanna Pettigrew; Angela Seaton; Catherine Wilson; Pamela J Maxwell; Silvia Berlingeri; Colin Purcell; Maryalice McGurk; Patrick G Johnston; David J J Waugh Journal: Mol Cancer Res Date: 2007-07-02 Impact factor: 5.852
Authors: Brian W Simons; Nicholas M Durham; Tullia C Bruno; Joseph F Grosso; Anthony J Schaeffer; Ashley E Ross; Paula J Hurley; David M Berman; Charles G Drake; Praveen Thumbikat; Edward M Schaeffer Journal: J Pathol Date: 2015-02 Impact factor: 7.996
Authors: Jessica M Haverkamp; Bridget Charbonneau; Scott A Crist; David K Meyerholz; Michael B Cohen; Paul W Snyder; Robert U Svensson; Michael D Henry; Hsing-Hui Wang; Timothy L Ratliff Journal: Prostate Date: 2011-01-12 Impact factor: 4.104